Axsome Therapeutics to present positive phase 3 results of ACCORD-2 trial of AXS-05 in AD agitation and SYMPHONY trial of AXS-12 in narcolepsy at the 2025 AAN meeting

Join Pharma | Login

	Editorial


	WALK THE EXTRA MILE
	Wednesday, April 2, 2025
	Global recognition to the Indian Pharmacopoeia (IP) as a book of standard has been a major issue the Indian pharmaceutical exporters, including the merchant exporters, have been facing for a long time now.
	Past Editorial...

TODAY'S NEWS


18:00 [IST]	Axsome Therapeutics to present positive phase 3 results of ACCORD-2 trial of AXS-05 in AD agitation and SYMPHONY trial of AXS-12 in narcolepsy at the 2025 AAN meeting
17:00 [IST]	Signs identified that precede sudden arrhythmic death syndrome in young people
16:00 [IST]	WHO brings countries together to test collective pandemic response
15:15 [IST]	FTCCI, ASCI and SCC highlight on reducing cancer mortality with technology
15:00 [IST]	UK MHRA approves eplontersen to treat adults with rare inherited nerve disease or polyneuropathy
14:50 [IST]	Apollo Hospitals’ Health of the Nation 2025 report states new era of preventive care emerging

more news >>

TOP NEWS


08:00 [IST]	Panel asks DoP to share data on quality checks and complaints against JAKs
08:00 [IST]	Exporters raise alarm as new NOC norms trigger export disruption
08:00 [IST]	TN DCA to get 18 new DIs next month to strengthen enforcement activities
08:00 [IST]	Parliamentary Panel recommends setting up of institutional mechanism for integration of systems of medicine
08:00 [IST]	Green hospitals evolving from being an option to a critical necessity to reduce environmental impact
08:00 [IST]	Reciprocal tariff may pose significant challenge to growth of medical devices sector: AiMeD

more news >>

YESTERDAY'S NEWS


18:00 [IST]	Intellia Therapeutics doses first patient in MAGNITUDE-2 phase 3 study of nexiguran ziclumeran
17:00 [IST]	Pacira BioSciences begins patient dosing in phase 2 study evaluating safety and efficacy of PCRX-201 to treat osteoarthritis of the knee
16:00 [IST]	Johnson & Johnson Global Survey reveals confidence in AI and medical technology to address personalized needs of aging population and alleviate burnout among HCPs
15:00 [IST]	Vera Therapeutics completes full enrollment in pivotal ORIGIN phase 3 trial for Atacicept in patients with IgA nephropathy
14:00 [IST]	Clinical Trials Information System designated as WHO primary registry
19:15 [IST]	Supreme Court issues notice to Roche on risiplam matter

more news >>

INTERVIEW


All DIs in TN are fully competent to inspect manufacturing units as per Revised Schedule M: MN Sridhar
MN Sridhar, director of the Tamil Nadu Drugs Control Department

Past Interviews...

	What's New?

US tariff exemption to bolster Indian pharma global presence with supply of high quality medicines Insulin Aspart 100 Iu/ml, Pack Of 3 Ml Brivaracetam 100mg Tab Mebeverine 135mg Tab Levofloxacin 500mg 100ml Infusion

Opinion Poll

Will the introduction of Revised Schedule M by Union Health Ministry solve the issue of quality of Indian drugs?

YesNoCan't Say

View Past Poll

Corporate

Special Features

Features

Chronicle Pharmabiz Specials

Forthcoming Events

TENDERS & PROJECTS

	Tenders & Enquiries
	Pharma Projects

CORPORATE

	Company Profile
	Corporate Results
	Corporate X-ray
	Pharmabiz Studies of Top Companies

US FDA UPDATE

EXPORT & IMPORT

	Drug Export Procedures
	Drug Units With WHO GMP Certification
	Pharma Export Data
	Import Reg. Update

PHARMA LAWS & DOCUMENTS

LIST OF LABS & GOVT. BODIES

	Govt Recognised In-House R&D Units
	AICTE Boards & Committees
	List of Indian CROs
	List of CROs (International)
	Govt & approved labs of India
	List of State Drugs Controllers